Brief: CytomX Therapeutics Announces Nomination Of Second Clinical Candidate In Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration With Astellas
03/04/2024 13:35
April 3 (Reuters) - CytomX Therapeutics Inc CTMX.O :
* CYTOMX THERAPEUTICS ANNOUNCES NOMINATION OF SECOND
CLINICAL
CANDIDATE IN BROAD PROBODY® T-CELL ENGAGING BISPECIFIC (TCB)
COLLABORATION WITH ASTELLAS
* CYTOMX THERAPEUTICS INC: CYTOMX-RETAINS US
CO-COMMERCIALIZATION
AND ECONOMIC RIGHTS FOR SELECT PROGRAMS
Source text for Eikon: ID:nGNX4ht79Y
Further company coverage: CTMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway